MarketFriction

Kwality Pharmaceuticals Ltd

NSE KPL · BSE 539997 · Pharmaceuticals
₹3,564.40 -2.11%
NSE close2026-10-01
52 week range1,561.00 - 3,949.00
Market cap₹3,758 Cr.
P/E46.0
Price band 20% Delivery 45.1%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales707892809084116111111123157162
Expenses54617163706790878693118121
Operating Profit151721172018262425303941
OPM %22%21%22%22%22%21%22%22%23%24%25%25%
Other Income01-7001101-011
Interest233232233233
Depreciation555455555555
Profit before tax8106111311191718223234
Tax %24%21%29%25%33%25%24%30%23%28%20%25%
Net Profit684889141214162526
EPS in Rs6.017.414.208.068.168.2213.9611.5013.6115.4324.3824.69
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7498137166139262456251307370503554
Expenses6989126150125233285190241290385419
Operating Profit5912161429172616680118135
OPM %7%9%8%9%10%11%38%24%22%22%24%24%
Other Income0111424-14-5222
Interest1222333710101111
Depreciation233346111520182020
Profit before tax26711112116226315489106
Tax %48%42%39%31%25%30%26%25%24%26%25%
Net Profit13488151201924406781
EPS in Rs1.553.234.397.288.0214.60115.6418.6722.9438.4164.9178.11
Dividend Payout %0%9%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth21%14%26%38%
Compounded Profit Growth44%35%29%88%
Stock Price CAGR67%34%115%290%
Return on Equity26%27%18%23%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital455101010101010101010
Reserves15172019273651171190214254321
Borrowings8131926293541549098112130
Other Liabilities10172640395264105707271130
Total Liabilities37517196105133166341361394447592
Fixed Assets1313172029435792120139146156
CWIP000000312140017
Investments124554500000
Other Assets243750707186102237226255302420
Total Assets37517196105133166341361394447592
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1-34-1146276141435317
Cash from Investing Activity-1-2-7-6-12-18-23-63-48-26-29-35
Cash from Financing Activity1655-212161-17-147
Net Cash Flow102-1-0043-6-110-11
Free Cash Flow-0-5-2-72-1235-41728-29
CFO/OP51%-30%76%21%108%62%115%59%78%67%85%32%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6389849884795055104136152203
Inventory Days6167715434943897310187167111
Days Payable4063658052965863117106112144
Cash Conversion Cycle8593907367773090297217208170
Working Capital Days354120182043246011810198128
ROCE %9%13%19%19%22%18%26%98%19%16%18%24%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters54.76%54.76%54.82%54.82%54.82%54.82%54.82%54.82%54.82%54.82%54.87%54.86%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.50%2.79%3.13%
DIIs0.01%0.01%0.00%0.00%0.02%0.03%0.32%0.33%0.33%0.33%0.36%0.56%
Public45.22%45.22%45.17%45.18%45.15%45.14%44.86%44.86%44.83%44.33%41.99%41.45%
No. of Shareholders6,2915,7865,6955,2737,4878,9479,42010,11511,59510,70910,55513,279

Fundamentals

Market Cap₹ 3,758 Cr.
Current Price₹ 3,625
Stock P/E46.0
Book Value₹ 320
ROCE24.1 %
ROE22.6 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)38%
Compounded Profit Growth (TTM)88%
Consolidated figures.
Valuation
Market capRs 3,698 Cr
Enterprise valueRs 3,825 Cr
P/E (TTM)45.63x
Price to book11.15x
Price to sales6.68x
EV / EBITDA27.85x
EV / EBIT32.60x
EV / sales6.91x
Price to cash flow216.79x
Earnings yield2.19%
P/E, 3-year average20.20x
P/B, 3-year average3.13x
P/E, 5-year average16.42x
P/B, 5-year average2.86x
Profitability
Operating margin (excl. other income)23.50%
Operating margin (incl. other income)23.91%
EBITDA margin24.80%
Pre-tax margin19.22%
Net profit margin14.63%
Net margin, latest quarter15.78%
ROE22.61%
ROCE23.96%
ROA12.96%
ROE, 3-year average16.71%
ROCE, 3-year average18.61%
ROA, 3-year average9.58%
ROE, 5-year average31.87%
ROCE, 5-year average33.10%
ROA, 5-year average16.32%
ROIC (approx.)19.26%
Tax rate24.74%
Other income / net worth0.61%
Growth
Sales growth (latest year)35.89%
Profit growth (latest year)69.01%
Sales CAGR, 3 years26.08%
Sales CAGR, 5 years13.94%
Profit CAGR, 3 years51.50%
Profit CAGR, 5 years34.77%
Sales growth QoQ3.34%
Profit growth QoQ1.26%
Sales growth YoY (latest quarter)45.63%
Profit growth YoY (latest quarter)114.75%
Per share
EPS (TTM)Rs 78.11
EPS (latest year)Rs 64.91
EPS (latest quarter)Rs 24.69
EPS, 3-year averageRs 42.08
EPS, 5-year averageRs 52.11
Book value per shareRs 319.58
Sales per shareRs 533.87
Cash flow per shareRs 16.44
Free cash flow per shareRs -27.95
Efficiency
Asset turnover0.85x
Fixed asset turnover3.23x
Inventory turnover3.68x
Inventory days99 days
Debtor days203 days
Debtors turnover1.80x
Creditor days144 days
Cash conversion cycle170 days
Working capital days128 days
Leverage
Total debtRs 130 Cr
Cash and bankRs 4 Cr
Net debtRs 127 Cr
Debt to equity0.39x
Net debt / EBITDA0.92x
Interest coverage10.79x
Owners' fund to total sources55.99%
Debt to assets22.03%
Cash flow
Cash from Operating Activity (latest year)Rs 17 Cr
Cash from Investing Activity (latest year)Rs -35 Cr
Cash from Financing Activity (latest year)Rs 7 Cr
Net Cash Flow (latest year)Rs -11 Cr
Free cash flow (latest year)Rs -29 Cr
FCFE (approx.: FCF + change in debt)Rs -11 Cr
Cash from ops / profit, 5 years0.80x
Sales to cash flow29.49x
Statement figures
Net sales (TTM)Rs 554 Cr
Net sales (latest year)Rs 503 Cr
Sales (latest quarter)Rs 162 Cr
Operating profit excl. other income (latest year)Rs 118 Cr
Operating profit (latest quarter)Rs 41 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 137 Cr
PBDT (TTM)Rs 126 Cr
Profit before tax (TTM)Rs 106 Cr
Tax (latest year)Rs 22 Cr
Net profit (TTM)Rs 81 Cr
Net profit (latest year)Rs 67 Cr
Net profit (latest quarter)Rs 26 Cr
Depreciation (TTM)Rs 20 Cr
Depreciation (latest quarter)Rs 5 Cr
Interest (TTM)Rs 11 Cr
Cost of goods sold (latest year)Rs 288 Cr
Total expenditure (latest year)Rs 385 Cr
Total income (latest year)Rs 505 Cr
Share capitalRs 10 Cr
ReservesRs 321 Cr
Shareholders' fundsRs 332 Cr
Total assetsRs 592 Cr
Net blockRs 156 Cr
Capital work in progressRs 17 Cr
ReceivablesRs 280 Cr
InventoryRs 78 Cr
Other liabilitiesRs 130 Cr
Shares outstanding (crore)1.04
Ownership
Promoter holding54.86% (+0.04 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 45.6 is at the 95th percentile of its own 9.2-year range (median 16.0, low 2.2, high 69.5).
P/B 11.15 is at the 95th percentile (median 2.11).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodKPLNifty 50Difference
1 week-2.1%-2.8% +0.6 pts
1 month+5.1%-6.8% +11.9 pts
3 months+33.1%-7.6% +40.7 pts
3 years+882.7%+14.2% +868.6 pts
5 years+305.6%+27.9% +277.7 pts
1 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 1 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.09%0 -16%

Red flags

F-score 7 of 8
explainReceivables outrunning sales Receivables grew 81% vs sales +36% in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹162 Cr +45.9% vs Jun 2025. Net profit ₹26 Cr +116.7%.
Against our estimate for Jun 2026: sales +3.6%, profit +29.8% beat. Our estimate for Sep 2026: sales Rs 156 Cr, profit Rs 23 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 100perc in previous 365 daysClose to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 months

Quick answers

What is the market cap of Kwality Pharmaceuticals Ltd?

Kwality Pharmaceuticals Ltd (KPL) has a market capitalisation of Rs 3,758 Cr. at the 2026-10-01 close.

What is the P/E ratio of Kwality Pharmaceuticals Ltd?

Kwality Pharmaceuticals Ltd trades at a P/E of 46.0 on trailing twelve-month profit, at the 2026-10-01 close.

What were Kwality Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Kwality Pharmaceuticals Ltd sales was Rs 162 Cr (+45.9% vs Jun 2025) and net profit was Rs 26 Cr.

What is the 52-week high and low of Kwality Pharmaceuticals Ltd?

The 52-week high is Rs 3,949.00 and the 52-week low is Rs 1,561.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03